159 related articles for article (PubMed ID: 32278292)
1. Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry.
Li W; Perpinioti N; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122098. PubMed ID: 32278292
[TBL] [Abstract][Full Text] [Related]
2. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
3. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Drilon A; Ou SI; Cho BC; Kim DW; Lee J; Lin JJ; Zhu VW; Ahn MJ; Camidge DR; Nguyen J; Zhai D; Deng W; Huang Z; Rogers E; Liu J; Whitten J; Lim JK; Stopatschinskaja S; Hyman DM; Doebele RC; Cui JJ; Shaw AT
Cancer Discov; 2018 Oct; 8(10):1227-1236. PubMed ID: 30093503
[TBL] [Abstract][Full Text] [Related]
4. Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Dogan-Topal B; Li W; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Mar; 1110-1111():116-123. PubMed ID: 30802754
[TBL] [Abstract][Full Text] [Related]
5. Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Retmana IA; Loos NHC; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122718. PubMed ID: 33957355
[TBL] [Abstract][Full Text] [Related]
6. Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates.
Sparidans RW; Li W; Schinkel AH; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2018 Nov; 161():136-143. PubMed ID: 30149189
[TBL] [Abstract][Full Text] [Related]
7. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
[TBL] [Abstract][Full Text] [Related]
9. Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Li W; Schinkel AH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Aug; 1122-1123():78-82. PubMed ID: 31163324
[TBL] [Abstract][Full Text] [Related]
10. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2014 Jan; 88():216-20. PubMed ID: 24080524
[TBL] [Abstract][Full Text] [Related]
11. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Şentürk R; Wang Y; Schinkel AH; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jun; 1147():122131. PubMed ID: 32416592
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
13. Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study.
Tibben MM; Huijberts S; Li W; Schinkel AH; Gebretensae A; Rosing H; Beijnen JH
J Pharm Biomed Anal; 2019 Sep; 173():169-175. PubMed ID: 31146172
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.
Dolman ME; Westerhout EM; Hamdi M; Schellens JH; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2015 Mar; 107():403-8. PubMed ID: 25659532
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
[TBL] [Abstract][Full Text] [Related]
16. Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry.
Spatari C; Li W; Schinkel AH; Ragno G; Schellens JHM; Beijnen JH; Sparidans RW
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1083():204-208. PubMed ID: 29550682
[TBL] [Abstract][Full Text] [Related]
17. An aqueous normal-phase chromatography coupled with tandem mass spectrometry method for determining unbound brain-to-plasma concentration ratio of AZD1775, a Wee1 kinase inhibitor, in patients with glioblastoma.
Wu J; Sanai N; Bao X; LoRusso P; Li J
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1028():25-32. PubMed ID: 27318641
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat.
Široká J; Čečková M; Urbánek L; Kryštof V; Gucký T; Hofman J; Strnad M; Štaud F
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1089():24-32. PubMed ID: 29753211
[TBL] [Abstract][Full Text] [Related]
20. Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry.
Qiu F; Gu Y; Wang T; Gao Y; Li X; Gao X; Cheng S
Biomed Chromatogr; 2016 Jun; 30(6):962-8. PubMed ID: 26467669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]